Qiagen N.V. (NASDAQ:QGEN) – Equities research analysts at William Blair reduced their FY2018 earnings per share (EPS) estimates for Qiagen N.V. in a report issued on Monday. William Blair analyst B. Weinstein now forecasts that the company will earn $1.40 per share for the year, down from their previous forecast of $1.41.
Other research analysts have also issued research reports about the company. TheStreet raised Qiagen N.V. from a “c” rating to a “b” rating in a report on Monday, June 5th. Evercore ISI upped their price objective on Qiagen N.V. from $30.00 to $31.50 and gave the stock an “outperform” rating in a report on Thursday, May 4th. BidaskClub lowered Qiagen N.V. from a “strong-buy” rating to a “buy” rating in a report on Saturday, June 10th. Jefferies Group LLC reaffirmed a “hold” rating and set a $28.00 price objective (up previously from $25.00) on shares of Qiagen N.V. in a report on Monday. Finally, Independent Research GmbH raised Qiagen N.V. from a “sell” rating to a “hold” rating in a report on Tuesday. Eight analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $32.28.
Shares of Qiagen N.V. (QGEN) traded up 0.43% during midday trading on Tuesday, hitting $32.98. 437,606 shares of the stock were exchanged. The firm has a 50 day moving average of $34.00 and a 200-day moving average of $31.00. The company has a market cap of $7.53 billion, a price-to-earnings ratio of 100.86 and a beta of 1.15. Qiagen N.V. has a one year low of $24.86 and a one year high of $35.26.
Qiagen N.V. (NASDAQ:QGEN) last issued its quarterly earnings data on Thursday, July 27th. The company reported $0.30 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. The business had revenue of $349 million for the quarter, compared to analysts’ expectations of $353.09 million. Qiagen N.V. had a net margin of 5.44% and a return on equity of 10.98%. The business’s revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the company earned $0.24 EPS.
Several hedge funds have recently modified their holdings of QGEN. Hussman Strategic Advisors Inc. acquired a new position in Qiagen N.V. during the first quarter valued at $3,540,000. Canada Pension Plan Investment Board increased its position in Qiagen N.V. by 1,128.0% in the first quarter. Canada Pension Plan Investment Board now owns 481,483 shares of the company’s stock valued at $14,012,000 after buying an additional 442,274 shares during the period. Exane Derivatives increased its position in Qiagen N.V. by 427.6% in the first quarter. Exane Derivatives now owns 82,944 shares of the company’s stock valued at $2,413,000 after buying an additional 67,224 shares during the period. Wetherby Asset Management Inc. increased its position in Qiagen N.V. by 1.8% in the first quarter. Wetherby Asset Management Inc. now owns 9,273 shares of the company’s stock valued at $269,000 after buying an additional 163 shares during the period. Finally, First Mercantile Trust Co. increased its position in Qiagen N.V. by 27.3% in the first quarter. First Mercantile Trust Co. now owns 14,593 shares of the company’s stock valued at $422,000 after buying an additional 3,126 shares during the period. Institutional investors and hedge funds own 60.45% of the company’s stock.
Qiagen N.V. Company Profile
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
What are top analysts saying about Qiagen N.V.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Qiagen N.V. and related companies.